Beukelman T, et al. - The purpose of this trial was to examine if the use of tumour necrosis factor inhibitor (TNFi) was associated with an increased rate of incident malignancy compared with no TNFi use in the treatment of juvenile idiopathic arthritis (JIA), paediatric inflammatory bowel disease (pIBD) and paediatric plaque psoriasis (pPsO). In comparison to the general population, children diagnosed with JIA, pIBD and pPsO reported an increased rate of malignancy. The risk was not significantly increased when treated with TNFi compared to no TNFi use.